Opening up data at the European Medicines Agency
BMJPublished 10 May 2011
Peter C Gøtzsche, Andreas Jørgensen
Citations105
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
Peter Gøtzsche and Anders Jørgensen describe their efforts to get access to unpublished trial reports from the European Medicines Agency.
Abstract
Widespread selective reporting of research results means we don't know the true benefits and harms of prescribed drugs. Peter Gøtzsche and Anders Jørgensen describe their efforts to get access to unpublished trial reports from the European Medicines Agency
Keywords
MedicinePharmacology, Toxicology and Pharmaceutics
New England Journal of MedicineSelective Publication of Antidepressant Trials and Its Influence on Apparent Efficacy
2,426 Citations2008Erick H. Turner, Annette M. Matthews +3 more
A systematic literature search found that among 74 FDA-registered studies, 31%, accounting for 3449 study participants, were not published, and the increase in effect size ranged from 11 to 69% for individual drugs and was 32% overall.
JAMAEmpirical Evidence for Selective Reporting of Outcomes in Randomized Trials
1,806 Citations2004An‐Wen Chan, Asbjørn Hróbjartsson +3 more
The reporting of trial outcomes is not only frequently incomplete but also biased and inconsistent with protocols and Published articles, as well as reviews that incorporate them, may therefore be unreliable and overestimate the benefits of an intervention.
BMJEvidence b(i)ased medicine—selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications
639 Citations2003Hans Melander, Jane Ahlqvist-Rastad +2 more
Any attempt to recommend a specific selective serotonin reuptake inhibitor from the publicly available data only is likely to be based on biased evidence.
Cochrane Database of Systematic ReviewsLong-term pharmacotherapy for obesity and overweight
379 Citations2003Raj Padwal, Diana Rucker +3 more
Average weight losses with current anti-obesity agents appear modest but may be of clinical benefit, and better studies designed to examine mortality and cardiovascular morbidity are required to fully evaluate any potential benefit of such agents.
New England Journal of MedicineOutcome Reporting in Industry-Sponsored Trials of Gabapentin for Off-Label Use
362 Citations2009S. Swaroop Vedula, Lisa Bero +2 more
Examination of reporting practices for trials of gabapentin funded by Pfizer and Warner-Lambert's subsidiary, Parke-Davis for off-label indications found selective outcome reporting threatens the validity of evidence for the effectiveness of off- label interventions.
PLoS MedicineReporting Bias in Drug Trials Submitted to the Food and Drug Administration: Review of Publication and Presentation
322 Citations2008Kristin L. Rising, Peter Bacchetti +1 more
The publication rate of efficacy trials submitted to the Food and Drug Administration in approved New Drug Applications (NDAs) is determined and the trial characteristics as reported by the FDA with those reported in publications are compared.
International Journal of CardiologyThe effect of lorcainide on arrhythmias and survival in patients with acute myocardial infarction: an example of publication bias
75 Citations1993Alison Cowley, A. M. Skene +2 more
There were nine deaths among the 49 patients treated with lorcainide compared with only one in the patients given placebo, consistent with the results of the First and Second Cardiac Arrhythmia Suppression trials (CAST and CAST-II).
BMJFDA is incapable of protecting US “against another Vioxx”
54 Citations2004Jeanne Lenzer
The approval of rofecoxib (Vioxx) by the US Food and Drug Administration has led to the “single greatest drug safety catastrophe” in the history of this country or the world, charged one of the agency's own experts in US Senate hearings.